138 related articles for article (PubMed ID: 27651919)
21. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
22. Markers of vascular damage in lupus pregnancy.
Direskeneli H; Buchanan NM; Khamashta MA; Keser G; D'Cruz D; Hughes GR
Clin Exp Rheumatol; 1997; 15(5):535-9. PubMed ID: 9307862
[TBL] [Abstract][Full Text] [Related]
23. Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA.
Vanhoorelbeke K; Pareyn I; Schlammadinger A; Vauterin S; Hoylaerts MF; Arnout J; Deckmyn H
Thromb Haemost; 2005 Jan; 93(1):165-71. PubMed ID: 15630508
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
25. A comparative in vitro evaluation of six von Willebrand factor concentrates.
Lethagen S; Carlson M; Hillarp A
Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
[TBL] [Abstract][Full Text] [Related]
26. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
27. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
[TBL] [Abstract][Full Text] [Related]
28. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
30. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
Aihara M; Kimura A; Chiba Y; Yoshida Y
Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
[TBL] [Abstract][Full Text] [Related]
31. A comparative evaluation of a new automated assay for von Willebrand factor activity.
Lawrie AS; Stufano F; Canciani MT; Mackie IJ; Machin SJ; Peyvandi F
Haemophilia; 2013 Mar; 19(2):338-42. PubMed ID: 23205618
[TBL] [Abstract][Full Text] [Related]
32. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study.
Stuijver DJ; Piantanida E; van Zaane B; Galli L; Romualdi E; Tanda ML; Meijers JC; Büller HR; Gerdes VE; Squizzato A
Haemophilia; 2014 May; 20(3):326-32. PubMed ID: 24118466
[TBL] [Abstract][Full Text] [Related]
33. Platelet Function Tests and Inflammatory Markers for the Differentiation of Primary Thrombocytosis and Secondary Thrombocytosis.
Kanya P; Rattarittamrong E; Wongtakan O; Rattanathammethee T; Chai-Adisaksopha C; Tantiworawit A; Norrasethada L
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2079-2085. PubMed ID: 31350969
[TBL] [Abstract][Full Text] [Related]
34. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.
Cabrera N; Moret A; Caunedo P; Cid AR; Vila V; España F; Aznar JA
Haemophilia; 2013 Nov; 19(6):920-5. PubMed ID: 23730809
[TBL] [Abstract][Full Text] [Related]
35. [Hematostatic function in myeloproliferative diseases].
Zhu X; Pei MF; Xu M; Zhang GS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):1013-6. PubMed ID: 17096909
[TBL] [Abstract][Full Text] [Related]
36. Increased von Willebrand factor antigen in the plasma of patients with vasculitis.
Nusinow SR; Federici AB; Zimmerman TS; Curd JG
Arthritis Rheum; 1984 Dec; 27(12):1405-10. PubMed ID: 6508862
[TBL] [Abstract][Full Text] [Related]
37. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance.
de Maistre E; Volot F; Mourey G; Aho LS; Ternisien C; Briquel ME; Bertrand MA; Tardy B; Frotscher B; Nguyen P; Dumont L; Vandroux D; Hézard N; Trossaërt M
Thromb Haemost; 2014 Oct; 112(4):825-30. PubMed ID: 25103956
[TBL] [Abstract][Full Text] [Related]
38. Platelet ligands and ADAMTS13 during Puumala hantavirus infection and associated thrombocytopenia.
Laine O; Mäkelä S; Mustonen J; Helminen M; Vaheri A; Lassila R; Joutsi-Korhonen L
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):468-72. PubMed ID: 21508829
[TBL] [Abstract][Full Text] [Related]
39. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
40. Blood coagulation system in patients with chronic kidney disease: a prospective observational study.
Huang MJ; Wei RB; Wang Y; Su TY; Di P; Li QP; Yang X; Li P; Chen XM
BMJ Open; 2017 Jun; 7(5):e014294. PubMed ID: 28576889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
